NCT02942095View on ClinicalTrials.gov

Study of Ixazomib and Erlotinib in Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 6, 2017

Primary Completion Date

December 7, 2022

Study Completion Date

December 7, 2022

Conditions
Solid Tumors
Interventions
DRUG

Ixazomib

"Dose Escalation Phase Starting Dose: Ixazomib 3.0 mg on Days 1, 8, and 15 of a 28-day cycle.~Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase"

DRUG

Erlotinib

Dose Escalation and Dose Expansion Phase: Erlotinib 150 mg by mouth on Days 1 - 28 of a 29 day cycle.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Millennium: The Takeda Oncology Company

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT02942095 - Study of Ixazomib and Erlotinib in Solid Tumors | Biotech Hunter | Biotech Hunter